Tendon anti-adhesion membrane for strengthening tendon anastomotic stoma

The three-layer tendon anti-adhesion membrane solves the deficiencies of existing materials in mechanical support and drug delivery, achieves the matching of material degradation and tendon healing period, and the dynamic matching of drug release and inflammation progression, providing continuous mechanical support and effective inflammation control.

CN120617641APending Publication Date: 2025-09-12龚琼
0 Cites 0 Cited by

Patent Information

Application Number
CN202510863012.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-06-25
Publication Date
2025-09-12

AI Technical Summary

Technical Problem

Existing tendon anti-adhesion materials have deficiencies in mechanical support and biological barrier function, and the drug delivery system is not designed reasonably, which leads to premature degradation of materials, imbalanced drug release, increased risk of tendon rupture and insufficient inflammation control.

Method used

The tendon anti-adhesion membrane adopts a three-layer structure, the inner layer is a polycaprolactone and nano-hydroxyapatite reinforced fiber layer, the middle layer is a PLGA drug-loaded microsphere layer, and the outer layer is a cross-linked modified hyaluronic acid barrier layer. It is prepared by electrospinning and cross-linking technology to achieve a synergistic effect of mechanical support, drug sustained release and biological barrier.

Benefits of technology

The material degradation cycle is matched with the tendon healing period, and the drug release curve is dynamically matched with the progression of inflammation, reducing the risk of secondary injury and adhesion, and providing continuous mechanical support and effective inflammation control.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides an anti-adhesion composite membrane for tendon repair. The anti-adhesion composite membrane comprises a polycaprolactone / nano-hydroxyapatite fiber reinforced layer, a PLGA (poly (lactic-co-glycolic acid)) double-drug-loaded microsphere sustained-release layer and a modified hyaluronic acid barrier layer from inside to outside. According to the structure, the defects in the prior art are overcome in the following mode that the inner-layer nano-composite fiber provides mechanical support matched with the tendon; the middle-layer microspheres realize gradient release of the anti-inflammatory drug; the outer biological barrier inhibits fibroblast migration. The three-layer functional design synchronously meets the requirements of mechanical protection, drug controlled release and physical isolation; a double-drug synergistic system covers tendon healing complete cycle inflammation control; and the material degradation rate is accurately matched with the tissue regeneration process.
Need to check novelty before this filing date? Find Prior Art